ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NRBO NeuroBo Pharmaceuticals Inc

0.509
0.00 (0.0%)
Pre Market
Last Updated: 07:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.51
Ask Price 0.53
News -
Day High

Low
0.3611

52 Week Range

High
2.33

Day Low
Company Name Stock Ticker Symbol Market Type
NeuroBo Pharmaceuticals Inc NRBO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.509 07:00:00
Open Price Low Price High Price Close Price Prev Close
0.509
Trades Volume Avg Volume 52 Week Range
0 0 - 0.3611 - 2.33
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.509 USD

NeuroBo Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
19.79M 38.81M - 0 -13.97M -0.36 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

NeuroBo Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NRBO Message Board. Create One! See More Posts on NRBO Message Board See More Message Board Posts

Historical NRBO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.460.5360.430.494556107,3880.04910.65%
1 Month0.430.5360.41150.461459260,5260.07918.37%
3 Months0.480.540.40040.469107856,9050.0296.04%
6 Months0.4980.650.36110.5004042221,3580.0112.21%
1 Year1.382.330.36110.9414338665,507-0.871-63.12%
3 Years162.00228.2820.361141.62962,154-161.49-99.69%
5 Years274.50900.000.361144.88737,914-273.99-99.81%

NeuroBo Pharmaceuticals Description

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com